CClinicalTrials.gg
Active, not recruitingNCT05944601BDSC-MCIUpdated May 30, 2024

Exploring to Remediate Behavioral Disturbances of Spatial Cognition

An interventional study of Virtual and computer-based cognitive remediation training in Spatial Navigation, sponsored by Istituto Auxologico Italiano. Active, not recruiting at 1 site in Italy. Open to participants aged 65 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-30.

Sponsored by Istituto Auxologico Italiano · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Mar 2023, registered Jul 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
83
Allocation
Non-randomized
Ages
65 Years to 85 Years
Sex
All
01

Study summary

Spatial navigation (SN) has been reported to be one of the first cognitive domains to be affected in Alzheimer's disease (AD), which occurs as a result of progressive neuropathology involving specific brain areas. Moreover, the epsilon 4 isoform of Apolipoprotein-E (APOE-ε4) has been associated with both sporadic and familial late-onset AD and patients with Mild Cognitive Impairment (MCI) due to AD are more likely to progressively deteriorate. It will be investigated (i) whether amyloid-positive MCI patients and APOE-ε4 carriers show subtle changes of SN prior to the overt symptoms of AD disorientation, both in virtual and in naturalistic open-space tasks, and (ii) the effect of a combined treatment of computer-based and virtual reality tasks in those presenting such an impairment. Finally, (iii) threshold algorithms based on physiological parameters and gait analysis will be set up to support senior citizens at increased risk in maintaining their ability to independently navigate urban environments. Different types of navigational guidance will be examined on a sample of 76 older adults by the AppleGame, and the Detour Navigation Test-modified version. It is expected that patients with MCI due to AD and APOE-ε4 carriers show reduced SN performances than individuals with subjective cognitive impairment and healthy controls in the experimental tasks, with potential improvements after cognitive rehabilitation. Altered SN performances of individuals at increased risk to develop AD may inform future advanced technological applications in providing valuable information on threshold algorithms based on physiological parameters and gait analysis during elders' traveling to unfamiliar locations.

Read the detailed description

Alzheimer's disease (AD) is characterized by a progressive deterioration of cognitive functions with episodic memory loss and spatial disorientation (SD) as main features. Getting lost in community due to AD is associated with a wide range of negative consequences, such as a strong decrease in patients' quality of life. Episodes of SD in the elderly can increase the possibility of being recovered in a nursing home, caused by a loss of the sense of autonomy as well as an increase in potential injuries and, in the worst cases, even death. Additionally, caregiver burden and increased stress, as well as scarce community resources represent other significant problems related to patients' SD. New technological solutions, such as virtual reality (VR), represent promising means for AD assessment and intervention, especially when they can reveal poor ecological performances. In addition to the advanced age, the ε4 allele of Apolipoprotein-E (APO-E) represents the most important risk factor for AD, providing the opportunity to evaluate subclinical behavioral alterations in individuals with subjective cognitive decline (SCD), and Mild Cognitive Impairment (MCI) due to AD, which represents the prodromic phase of dementia. Deterioration of spatial navigation (SN) abilities is often present early in the course of AD. Therefore, a better understanding the neural mechanisms related to SN impairment in patients at high risk of developing AD can help timely diagnosis and intervention. The present study, adopting a technological apparatus for the detection and the rehabilitation of SN deficits, aims to: (i) investigate the performances obtained on SN tasks in a sample of community-dwelling older adults grouped into three levels (healthy controls, individuals with SCD and patients with MCI due to AD), undergoing virtual (The AppeGame) and naturalistic open-space tests (Detour Navigation Test-modified version); (ii) correct SN deficits by computer-based cognitive remediation sessions and VR sessions; (iii) educate participants at high risk of developing dementia about the opportunity offered by technology in supporting SN in exploring urban circuits.

We will analyze results of the virtual and ecological tasks of SN as a function of age, ApoE genotype and belonging of one the three groups, using a multiple linear regression model. The subgroups of participants at highest risk of developing AD will be administered the aforementioned combined cognitive rehabilitation sessions, with a test/retest analysis. Finally, through an online technological monitoring system, participants will be provided personalized feedbacks via smartphone digital health applications connected to a wearable equipped with sensors, in order to self-manage during their journeys alone in urban environments thanks to the use of threshold algorithms capable of supporting their SN.

02

Conditions studied

  • Spatial Navigation

Browse trials for

Keywords

  • spatial navigation
  • Alzheimer's disease
  • mild cognitive impairment
  • subjective cognitive decline
  • elderly
  • APOE
  • assistive technology
03

In context

Problem Behavior

517 studies on the registry are indexed under Problem Behavior; 92 are open to participants now.

This study's enrollment of 83 is close to the median of 90 across 391 interventional studies indexed under Problem Behavior.

Browse Problem Behavior studies →

Lead sponsor

Istituto Auxologico Italiano is the lead sponsor of 196 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • age over 65 years;
  • education not less than 5 years;
  • basic ICT skills measured by the Catholic University devoted software

Exclusion criteria

Exclusion Criteria:

  • presence of visual, hearing or motor impairment significantly interfering with spatial navigation tasks;
  • neurological/psychiatric disease or other medical conditions preventing spatial navigation;
  • history of alcohol or drugs addiction;
  • intake of psychotropic drugs;
  • presence of dementia.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • No intervention
    Healthy controls

    Elderly people without cognitive impairment or subjective cognitive decline.

  • No intervention
    Subjective cognitive decline

    Individuals presenting cognitive complains that are not confirmed by neuropsychological testing.

  • Experimental
    patients with MCI due to AD

    Patients with Mild Cognitive Impairment with abnormal spinal fluid test for amyloid beta protein.

    Behavioral: Virtual and computer-based cognitive remediation training

Interventions

  • BehavioralVirtual and computer-based cognitive remediation training

    Amyloid-positive MCI patients, and individuals carrying the ApoE- ε4 allele will undergo a combined intervention of computer-based sessions of a spatial memory task by the Erica software (Giunti, Florence, Italy) and VR navigation sessions by the NeuroVirtual 3D software (Serino et al., 2010), in order to improve spatial memory for landmarks location and mental frame syncing for supporting spatial scenarios, respectively. The intervention will last one month for a total of 12 sessions (3 days a week, 50 minutes per session).

06

What researchers measure

Primary outcomes

  1. Detecting drop errors (DEs) and composite disorientation score (CDS) in individuals at increased risk to develop AD in virtual and naturalistic spatial navigation tasks, respectively

    Lower performances in virtual navigation tasks (higher DEs) and in naturalistic navigation (CDS\>1) in patients with MCI due to AD and in APOE-e4 carriers than healthy controls and individuals with subjective cognitive decline

    Time frame: March-November 2023

Secondary outcomes

  1. Improving spatial memory after a combined cognitive training (virtual reality and computer-based cognitive remediation) in a subgroup of patients with MCI due to AD and APOE-e4 carriers

    Higher performances in the Corsi learning Suvra-span test

    Time frame: December 2023-January 2024

Other outcomes

  1. To educate a dyad (subject and caregiver) about the usefulness of a portable assistive technology for spatial navigation in community settings

    High scores in the Tele-healthcare Satisfaction Questionnaire-Wearable Technology

    Time frame: January 2023-February 2024

07

Study locations

1 site
  • Istituto Auxologico Italiano
    Milano, Lombardy 20149, Italy
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05944601
Lead sponsor
Istituto Auxologico Italiano
Responsible party
Sponsor
First posted
Jul 13, 2023
Start date
Mar 1, 2023
Primary completion
Feb 28, 2024
Completion
Jun 30, 2024 (estimated)
Last update
May 30, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion